miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines
Creators
- 1. Department of Surgery, Ohio State University Medical Center, Columbus, OH (United States)
- 2. College of Pharmacy, Ohio State University, Columbus, OH (United States)
- 3. Divisions of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN (United States)
- 4. Center for Liver Research, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata (India)
Description
Research highlights: → miR-199a-3p targets CD44 in HCC. → Proliferation and invasion are reduced by miR-199a-3p in CD44+ HCC. → miR-199a-3p is reduced and CD44 protein is increased in HCC tissues. → The duplex form of miR-199a-3p mimetic is required for activity. -- Abstract: Previous work by us and others reported decreased expression of miR-199a-3p in hepatocellular carcinoma (HCC) tissues compared to adjacent benign tissue. We report here a significant reduction of miR-199a-3p expression in 7 HCC cell lines. To determine if miR-199a-3p has a tumor suppressive role, pre-miR-199a-3p oligonucleotides were transfected into the HCC cell lines. Pre-miR-199a-3p oligonucleotide reduced cell proliferation by approximately 60% compared to control oligonucleotide in only two cell lines (SNU449 and SNU423); the proliferation of the other 5 treated cell lines was similar to control oligonucleotide. A pre-miR-199a-3p oligonucleotide formulated with chemical modifications to enhance stability while preserving processing, reduced cell proliferation in SNU449 and SNU423 to the same extent as the commercially available pre-miR-199a-3p oligonucleotide. Furthermore, only the duplex miR-199a-3p oligonucleotide, and not the guide strand alone, was effective at reducing cell viability. Since a CD44 variant was essential for c-Met signaling [V. Orian-Rousseau, L. Chen, J.P. Sleeman, P. Herrlich, H. Ponta, CD44 is required for two consecutive steps in HGF/c-Met signaling, Genes Dev. 16 (2002) 3074-3086] and c-Met is a known miR-199a-3p target, we hypothesized that miR-199a-3p may also target CD44. Immunoblotting confirmed that only the two HCC lines that were sensitive to the effects of pre-miR-199a-3p were CD44+. Direct targeting of CD44 by miR-199a-3p was confirmed using luciferase reporter assays and immunoblotting. Transfection of miR-199a-3p into SNU449 cells reduced in vitro invasion and sensitized the cells to doxorubicin; both effects were enhanced when hyaluronic acid (HA) was added to the cell cultures. An inverse correlation between the expression of miR-199a-3p and CD44 protein was noted in primary HCC specimens. The ability of miR-199a-3p to selectively kill CD44+ HCC may be a useful targeted therapy for CD44+ HCC.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.bbrc.2010.10.130Additional details
Identifiers
- DOI
- 10.1016/j.bbrc.2010.10.130;
- PII
- S0006-291X(10)02028-0;
Publishing Information
- Journal Title
- Biochemical and Biophysical Research Communications
- Journal Volume
- 403
- Journal Issue
- 1
- Journal Page Range
- p. 120-125
- ISSN
- 0006-291X
- CODEN
- BBRCA9
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 45025614
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- ANIMAL TISSUES; CELL CULTURES; CELL PROLIFERATION; DOXORUBICIN; HEPATOMAS; HYALURONIC ACID; IN VITRO; LIVER; LUCIFERASE; OLIGONUCLEOTIDES
- Descriptors DEC
- AMINES; ANTIBIOTICS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC DRUGS; BODY; CARBOHYDRATES; CARCINOMAS; DIGESTIVE SYSTEM; DISEASES; DNA; DRUGS; ENZYMES; GLANDS; MUCOPOLYSACCHARIDES; NEOPLASMS; NUCLEIC ACIDS; ORGANIC COMPOUNDS; ORGANS; OXIDASES; OXIDOREDUCTASES; POLYSACCHARIDES; PROTEINS; SACCHARIDES
Optional Information
- Copyright
- Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.